Sanofi SA (EPA:SAN)‘s stock had its “neutral” rating reaffirmed by equities researchers at J P Morgan Chase & Co in a report issued on Friday.

Other equities analysts also recently issued research reports about the company. UBS AG set a €82.00 ($97.62) price objective on Sanofi SA and gave the company a “neutral” rating in a research report on Wednesday, June 14th. Jefferies Group LLC set a €92.00 ($109.52) target price on Sanofi SA and gave the stock a “neutral” rating in a research report on Friday, May 12th. Berenberg Bank set a €97.00 ($115.48) target price on Sanofi SA and gave the stock a “neutral” rating in a research report on Thursday, May 11th. Goldman Sachs Group, Inc. (The) set a €82.00 ($97.62) target price on Sanofi SA and gave the stock a “neutral” rating in a research report on Wednesday, May 24th. Finally, Sanford C. Bernstein set a €90.00 ($107.14) target price on Sanofi SA and gave the stock a “neutral” rating in a research report on Monday, July 31st. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and five have given a buy rating to the company. Sanofi SA presently has a consensus rating of “Hold” and a consensus target price of €88.06 ($104.84).

Sanofi SA (SAN) opened at 82.21 on Friday. Sanofi SA has a one year low of €62.50 and a one year high of €92.97. The firm has a market capitalization of €103.24 billion and a price-to-earnings ratio of 11.47. The stock’s 50 day moving average price is €25.48 and its 200-day moving average price is €25.74.

TRADEMARK VIOLATION NOTICE: “Sanofi SA (SAN) Stock Rating Reaffirmed by J P Morgan Chase & Co” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/09/10/sanofi-sa-san-stock-rating-reaffirmed-by-j-p-morgan-chase-co.html.

About Sanofi SA

Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company operates in two segments, Pharmaceuticals and Vaccines. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Analyst Recommendations for Sanofi SA (EPA:SAN)

Receive News & Stock Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related stocks with our FREE daily email newsletter.